[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 2, 1997

From the Food and Drug Administration

Author Affiliations

Associate Commissioner for Health Affairs

JAMA. 1997;278(1):15. doi:10.1001/jama.1997.03550010027014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Public Hearing on Benzodiazepine Scheduling Criteria:  With participation from the National Institute on Drug Abuse and the Drug Enforcement Administration, the FDA will convene a hearing on the scheduling of benzodiazepines and benzodiazepine-related sub-stances. The purpose of this hearing, which will be held in Washington, DC, on September 11 and 12, 1997, is to gather evidence on possible ways to distinguish the abuse potential of different benzodiazepines, which will assist the federal government in scheduling reviews under the Controlled Substances Act.Benzodiazepines and related drug substances consistently rank among the most widely prescribed pharmaceuticals in the United States and are used extensively as anxiolytics, sedatives, muscle relaxants, and hypnotics. However, because of benzodiazepines' capacity to produce physical and psychological dependence, there are concerns over their misuse and the level of domestic and international control (scheduling) needed to prevent abuse.Recent studies suggest that it is possible to distinguish the pharmacological properties